Tomofumi Ando

This study shows that B-cell depletion or TIM-1 targeting enhances immunotherapy efficacy in HCC by reducing B-cell-mediated immunosuppression and improving antigen presentation.

This study shows that blocking CXCR4 and PD-1 together improves dendritic cell activation and immune responses against HCC in mouse models.

Liver fibrosis limits the survival benefit of multikinase inhibitor immunotherapy in hepatocellular carcinoma by promoting innate immune-mediated hepatotoxicity despite preserved tumor control.